SCHEMBL2159803

SCHEMBL2159803

Cc1nc(OCc2cccc(F)c2)ccc1C(=O)N[C@H](C)C1CCCCC1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.49
IDH1 O75874 1/20 0.43
CNR1 P21554 3/20 0.42
CNR2 P34972 3/20 0.42
MAOB P27338 2/20 0.41
MAOA P21397 1/20 0.41
CYP1A2 P05177 2/20 0.41
ABHD12 Q8N2K0 1/20 0.41
WDR5 P61964 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462248 1.00 GRM5 (0.49) GRM5IDH1CNR1CNR2MAOB
SCHEMBL6930986 0.89 GRM5 (0.46) GRM5IDH1CNR1CNR2MAOB
SCHEMBL6929958 0.87 CNR2 (0.56) IDH1CNR1CNR2ABHD12
SCHEMBL6930856 0.86 GRM5 (0.52) GRM5IDH1MAOBMAOACYP1A2
SCHEMBL12398895 0.85 GRM5 (0.68) GRM5
SCHEMBL6930884 0.85 GRM5 (0.68) GRM5
SCHEMBL6932033 0.85 GRM5 (0.68) GRM5
SCHEMBL6928147 0.84 NOX1 (0.48) CNR1CNR2CYP1A2ABHD12WDR5
SCHEMBL6929772 0.82 GRM5 (0.69) GRM5
SCHEMBL1462251 0.82 CHRM4 (0.47) GRM5IDH1CNR1CNR2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-07-28 US disclosed
WO-2011035324-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183980-A1 O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS GRM5, GRIK5, GRM1 GRM5 1/4885IDH1 750/4885CNR1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.